European Commission, Teva Pharmaceuticals

Drugmaker Teva Pharmaceuticals fined $500M by European regulators
Teva Pharmaceuticals is being fined $503 million (€463 million) by the European Commission for delaying competition posed by rival generic drugmakers, the company's second major financial penalty this month.
EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug
BRUSSELS (AP) — The European Commission said Thursday it has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its multiple sclerosis drug and for disparaging a rival company ...
Teva Hit With €463 Million EU Fine for Talking Down Rivals
Teva Pharmaceutical Industries Ltd. has been fined nearly €463 million ($503 million) by the European Union’s antitrust watchdog for thwarting fair competition by unfairly disparaging a rival maker of a multiple sclerosis drug.
Teva slapped with €463M fine over accusations it stymied Copaxone competition in Europe
Some two years after the European Commission accused Teva of meddling with the competition for its former multiple sclerosis blockbuster Copaxone, the other shoe has finally dropped. | The European Commission has fined Teva 462.
Teva fined $500M by EU for disparaging rival MS drug (update)
The European Commission has fined Israeli drugmaker Teva Pharmaceutical Industries (NYSE:TEVA) EUR 462.6M, or around $500M, for trying to ward off competition for its blockbuster multiple sclerosis drug Copaxone in Europe by disparaging a rival product.
Teva hit with $503 mln EU antitrust fine for disparaging rival product
The European Commission has fined Teva , the world's largest generic drugmaker, 462.6 million euros ($503 million) for abusing its dominant position to delay competition to its blockbuster multiple sclerosis medicine Copaxone,
EU Slaps 463-mn-euro Fine On World's Largest Generic Drugmaker Teva
The EU on Thursday slapped the world's largest generic drugmaker Teva with a 462.6-million-euro ($502 million) fine for "abusing its dominant position" to impede competition for its blockbuster multiple sclerosis medicine.
EU Commission fines drugmaker Teva €462 million over antitrust abuse
The European Commission fined the multinational pharmaceutical company Teva €462.6 million ($502 million) on Thursday for abusing its dominant market position. The European Union's top competition regulator said the drugmaker "artificially extended" the patent protection for Copaxone,
Teva Pharmaceutical Industries (TEVA) Scheduled to Post Quarterly Earnings on Wednesday
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) will be announcing its earnings results before the market opens ...
Teva long-acting olanzapine shows improvements in schizophrenia patients
Phase 3 trial results show Teva's TEV-'749 improves social functioning in adults with schizophrenia without post-injection ...
Yahoo Finance1d
Medincell’s partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241
Teva presented positive data from the initial period of the Phase 3 SOLARIS trial evaluating Olanzapine LAI in adult patients diagnosed with schizophrenia. Findings demonstrate significant ...
JD Supra12d
Teva Pharmaceuticals Pays $450 Million to Resolve Anti-Kickback and False Claims Act Violations
Teva Pharmaceuticals USA Inc. (Teva USA) and Teva Neuroscience Inc. (“Teva”) agreed to pay $450 million to resolve two matters that allege ...
Teva Presents IMPACT-TD Data On Tardive Dyskinesia, Revealing Patient Experience Variations
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new patient- and physician-reported ...
GlobalData on MSN20h
Teva’s long-lasting schizophrenia injectable shines in Phase III
Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...